COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Björk, Jonas, Bonander, Carl, Moghaddassi, Mahnaz, Rasmussen, Magnus, Malmqvist, Ulf, Inghammar, Malin, Kahn, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074397/
https://www.ncbi.nlm.nih.gov/pubmed/35514304
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200322
_version_ 1784701473520615424
author Björk, Jonas
Bonander, Carl
Moghaddassi, Mahnaz
Rasmussen, Magnus
Malmqvist, Ulf
Inghammar, Malin
Kahn, Fredrik
author_facet Björk, Jonas
Bonander, Carl
Moghaddassi, Mahnaz
Rasmussen, Magnus
Malmqvist, Ulf
Inghammar, Malin
Kahn, Fredrik
author_sort Björk, Jonas
collection PubMed
description We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.
format Online
Article
Text
id pubmed-9074397
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-90743972022-05-27 COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022 Björk, Jonas Bonander, Carl Moghaddassi, Mahnaz Rasmussen, Magnus Malmqvist, Ulf Inghammar, Malin Kahn, Fredrik Euro Surveill Rapid Communication We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection. European Centre for Disease Prevention and Control (ECDC) 2022-05-05 /pmc/articles/PMC9074397/ /pubmed/35514304 http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200322 Text en This article is copyright of the authors or their affiliated institutions, 2022. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Björk, Jonas
Bonander, Carl
Moghaddassi, Mahnaz
Rasmussen, Magnus
Malmqvist, Ulf
Inghammar, Malin
Kahn, Fredrik
COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
title COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
title_full COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
title_fullStr COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
title_full_unstemmed COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
title_short COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022
title_sort covid-19 vaccine effectiveness against severe disease from sars-cov-2 omicron ba.1 and ba.2 subvariants – surveillance results from southern sweden, december 2021 to march 2022
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074397/
https://www.ncbi.nlm.nih.gov/pubmed/35514304
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200322
work_keys_str_mv AT bjorkjonas covid19vaccineeffectivenessagainstseverediseasefromsarscov2omicronba1andba2subvariantssurveillanceresultsfromsouthernswedendecember2021tomarch2022
AT bonandercarl covid19vaccineeffectivenessagainstseverediseasefromsarscov2omicronba1andba2subvariantssurveillanceresultsfromsouthernswedendecember2021tomarch2022
AT moghaddassimahnaz covid19vaccineeffectivenessagainstseverediseasefromsarscov2omicronba1andba2subvariantssurveillanceresultsfromsouthernswedendecember2021tomarch2022
AT rasmussenmagnus covid19vaccineeffectivenessagainstseverediseasefromsarscov2omicronba1andba2subvariantssurveillanceresultsfromsouthernswedendecember2021tomarch2022
AT malmqvistulf covid19vaccineeffectivenessagainstseverediseasefromsarscov2omicronba1andba2subvariantssurveillanceresultsfromsouthernswedendecember2021tomarch2022
AT inghammarmalin covid19vaccineeffectivenessagainstseverediseasefromsarscov2omicronba1andba2subvariantssurveillanceresultsfromsouthernswedendecember2021tomarch2022
AT kahnfredrik covid19vaccineeffectivenessagainstseverediseasefromsarscov2omicronba1andba2subvariantssurveillanceresultsfromsouthernswedendecember2021tomarch2022

Ejemplares similares